Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
Table 2
Safety outcome for NVAF in all patients.
Safety outcome
Rivaroxaban (N = 127)
Apixaban (N = 126)
Event rate (%)
value
Event rate (%)
value
Major bleeding
BMI <25
0/25 = 0
1.000
4/32 = 12.5
0.036
BMI ≥25
2/102 = 2.0
0/94 = 0
BMI <30
0/68 = 0
0.214
4/71 = 5.6
0.131
BMI ≥30
2/59 = 3.4
0/55 = 0
Clinically relevant nonmajor bleeding (CRNMB)
BMI <25
11/25 = 44.0
0.004
2/32 = 6.3
0.352
BMI ≥25
15/102 = 14.7
13/94 = 13.8
BMI <30
15/68 = 22.1
0.634
9/71 = 12.7
1.000
BMI ≥30
11/59 = 18.6
6/55 = 10.9
Combined bleeding
BMI <25
11/25 = 44.0
0.006
6/32 = 18.8
0.570
BMI ≥25
17/102 = 16.7
13/94 = 24.4
BMI <30
15/68 = 22.1
0.997
13/71 = 18.3
0.250
BMI ≥30
13/59 = 22.0
6/55 = 10.9
Combined bleeding is a composite outcome of major bleeding and clinically relevant nonmajor bleeding. Chi-square, and Fisher’s exact tests for safety outcomes (major bleeding, CRNMB, and combined bleeding) in patients with BMI <25 versus ≥25 in the NVAF cohort.
